Iron Therapy

A single high dose of intravenous iron therapy has no significant effect on intact fibroblast growth factor 23 (FGF23) plasma levels for up to 7 days in normal and uraemic rats, new data indicate. These findings are of importance owing to the associations between increased mortality and FGF23 in patients with chronic kidney disease (CKD), who are often prescribed iron therapy.

The wide range of iron deficiency aetiologies from across the therapeutic spectrum as well as the most up-to-date advances in treatment, are highlighted in a comprehensive review by expert in the field and Iron Therapy Editorial Board member, Professor Michael Auerbach. The authors describe the far-reaching impact of iron deficiency on patients’ well-being and clinical outcomes, and further present intravenous iron therapy as an effective treatment alternative to oral iron.

Across multiple therapy areas, iron deficiency and its consequences have featured throughout publications and global congresses over the course of the last year. Provided below is an overview of the key updates in iron deficiency from throughout 2013. This summary highlights the trends in content related specifically to iron therapy and deficiency from three major congresses.

20Jeong et al recently reported the results of a retrospective observational study of 527 patients undergoing gastrectomy for gastric carcinoma. Patients with acute postoperative anaemia (haemoglobin <10 g/dL) received intravenous iron sucrose. Patients with preexisting, preoperative anaemia were excluded. A dose of 300 mg was administered every other day until reaching the total target amount, calculated as:

(body weight x [target haemoglobin – current haemoglobin] x 0.24) + 500 mg

Stefan Anker is Professor of cardiology and cachexia research at Charité Universitätsmedizin Berlin, Germany. He is active in biomarker, anaemia, metabolic, immunological and nutrition research, with a particular focus on developing new therapies for heart failure and for cachexia. Professor Anker currently serves on the Board of the European Heart Failure Association (HFA) and is President of the HFA (2012–2014).


Subscribe to RSS - Iron Therapy